Trial Profile
A phase 1, open-label, non-randomized, dose-finding, safety and tolerability study of orally administered Teysuno (S1) in combination with Epirubicin and Oxaliplatin in patients with advanced solid tumors - TPU-S1119
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Epirubicin; Oxaliplatin
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms TPU-S1119
- 11 Aug 2015 Status changed from recruiting to completed.
- 12 May 2014 New source identified and integrated (German Clinical Trials Register: DRKS00005941)
- 12 May 2014 New source identified and integrated (German Clinical Trials Register: DRKS00005941)